Chordate Medical publishes company description in connection with the change of listing to Nasdaq First North Growth Market

On January 31, 2022, Chordate announced that the Company has received preliminary approval from Nasdaq Stockholm AB ("Nasdaq") regarding the List change. The first day for trading on the Nasdaq First North Growth Market is tentatively February 15^th, 2022, subject to Chordate receiving final approval from Nasdaq, with the last day for trading on the Nordic SME being February 14^th, 2022. Provided that Chordate receives final approval from Nasdaq, the company's shares will continue to be traded under the short name CMH with the current ISIN code SE0009495559. Shareholders in Chordate will not have to take any action in the event of a change of trading venue.

The Company description is not deemed to contain any previously unpublished information that could have a material effect on the price of the Company's share.

Advisor
Västra Hamnen Corporate Finance AB is Chordate's advisor regarding the planned list change and Certified Adviser. Wistrand Advokatbyrå AB is Chordate's legal advisor.

Information:
This disclosure was submitted for publication, through the contact person below, on February 10th, 2022, at 16:00 am CET.

For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277
e-mail: [email protected]

Vastra Hamnen Corporate Finance AB, +46 40 200 250, [email protected], is Chordate's Certified Adviser.

The following documents can be retrieved from beQuoted
Chordate-Medical-publishes-company-description-in-connection.pdf

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM - SME (ticker: CMH). Read more at https://www.chordate.com/en/

If you want to open the text in your webbrowser click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected]

beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.

Vi hoppas att Du uppskattar denna service.